These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 15574786

  • 1. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
    Catley L, Tai YT, Shringarpure R, Burger R, Son MT, Podar K, Tassone P, Chauhan D, Hideshima T, Denis L, Richardson P, Munshi NC, Anderson KC.
    Cancer Res; 2004 Dec 01; 64(23):8746-53. PubMed ID: 15574786
    [Abstract] [Full Text] [Related]

  • 2. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
    Zhen YZ, Lin YJ, Liu XJ, Shang BY, Zhen YS.
    Anticancer Drugs; 2013 Jul 01; 24(6):609-16. PubMed ID: 23698252
    [Abstract] [Full Text] [Related]

  • 3. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, Carver B, Anderson KC.
    Cancer Res; 2005 Sep 15; 65(18):8350-8. PubMed ID: 16166312
    [Abstract] [Full Text] [Related]

  • 4. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 5. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
    Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Liu Y, Zhang Y, Azab F, Ngo HT, Issa GC, Quang P, Roccaro AM, Ghobrial IM.
    Clin Cancer Res; 2011 Apr 01; 17(7):1753-64. PubMed ID: 21355079
    [Abstract] [Full Text] [Related]

  • 6. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA.
    Mol Cancer Ther; 2006 Sep 01; 5(9):2378-87. PubMed ID: 16985072
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
    Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Mitsiades C, MItsiades N, Gong B, Bonham L, de Vries P, Munshi N, Richardson PG, Singer JW, Anderson KC.
    Cancer Res; 2003 Dec 01; 63(23):8428-36. PubMed ID: 14679006
    [Abstract] [Full Text] [Related]

  • 9. Synergistic effects of topoisomerase I inhibitor, SN38, on Fas-mediated apoptosis.
    Cao Y, Jin ZX, Tong XP, Yue S, Sakai T, Kawanami T, Sawaki T, Miki M, Iwao H, Nakajima A, Masaki Y, Fukushima Y, Fujita Y, Nakajima H, Okazaki T, Umehara H.
    Anticancer Res; 2010 Oct 01; 30(10):3911-7. PubMed ID: 21036702
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.
    Salem K, Brown CO, Schibler J, Goel A.
    Exp Hematol; 2013 Feb 01; 41(2):209-18. PubMed ID: 23063726
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
    Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC.
    Cancer Res; 2001 Apr 01; 61(7):3071-6. PubMed ID: 11306489
    [Abstract] [Full Text] [Related]

  • 15. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
    Podar K, Gouill SL, Zhang J, Opferman JT, Zorn E, Tai YT, Hideshima T, Amiot M, Chauhan D, Harousseau JL, Anderson KC.
    Oncogene; 2008 Jan 31; 27(6):721-31. PubMed ID: 17653083
    [Abstract] [Full Text] [Related]

  • 16. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
    Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB, Anderson KC.
    Blood; 2004 Apr 15; 103(8):3158-66. PubMed ID: 15070698
    [Abstract] [Full Text] [Related]

  • 17. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
    Cusack JC, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS.
    Cancer Res; 2001 May 01; 61(9):3535-40. PubMed ID: 11325813
    [Abstract] [Full Text] [Related]

  • 18. Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease.
    Khélifa T, Beck WT.
    Mol Pharmacol; 1999 Mar 01; 55(3):548-56. PubMed ID: 10051540
    [Abstract] [Full Text] [Related]

  • 19. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
    Hideshima T, Chauhan D, Ishitsuka K, Yasui H, Raje N, Kumar S, Podar K, Mitsiades C, Hideshima H, Bonham L, Munshi NC, Richardson PG, Singer JW, Anderson KC.
    Oncogene; 2005 Apr 28; 24(19):3121-9. PubMed ID: 15735676
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.